The Seed Investor
Early Stage Investing
Join our Newsletter  Hand-picked cannabis stocks, news & alerts straight to your inbox (100% FREE!)
  •  
  • Cannabis News
  • Marijuana Industry
  • Marijuana Investing
  • Psychedelics
  • Featured Companies
  • TSI Exclusive
  • About
    • Overview
    • Disclaimer
    • Advertise
    • Privacy Policy

Trending Now

  • MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies
  • Mind Cure Establishes Psychedelic Compound Research Program
  • Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer
  • MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
  • Why Psychedelics Micro-Dosing Applications Have The Inside Track On Commercialization
  • Cannabis Sales Soar 48% In 2019, 2020 Looking Even Stronger
Psychedelic Stocks
Exploring the companies and themes that make up this emerging and exciting new sector

MindMed Board of Directors Approves Reverse Share Split

2022-08-05 PSW Editor

Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

2022-08-04 PSW Editor

Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

2022-07-28 PSW Editor

Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

2022-07-19 PSW Editor

Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

2022-07-06 PSW Editor

Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.

Red Light Holland and Superstar Wiz Khalifa to Launch Naturally Occurring Psilocybin and Mushrooms Wellness Brand: Mistercap

2022-06-30 PSW Editor

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland's MISTERCAP brand of psilocybin-based products.

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

2022-06-27 PSW Editor

Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

2022-06-23 PSW Editor

Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.

Numinus Pilots Mental Health Program for Corporate Clients in Utah

2022-06-23 PSW Editor

Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

2022-06-21 PSW Editor

Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

2022-06-20 PSW Editor

Optimi files an application with Health Canada to synthesize, process and produce pharmaceutical grade 3,4-Methylenedioxymethamphetamine ("MDMA").

Numinus completes acquisition of Novamind and announces executive appointments

2022-06-13 PSW Editor

Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.

  • 1
  • 2
  • 3
  • 4
  • ...
  • 74
  • Next
Join our Newsletter
 Hand-picked cannabis stocks, news & alerts straight to your inbox (100% FREE!)

The Seed Investor Exclusive

MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies

MCUR’s $10 Million Financing Triples Cash Reserves, Powers Operations Strategies

2021-01-21
Mind Cure announces a CAD$10 million bought deal financing at a unit price of CAD$0.60. Proceeds will be directed toward product research development and related tech initiatives like its iSTRYM digital therapeutics platform.

Mind Cure Establishes Psychedelic Compound Research Program

Compass Pathways Files For NASDAQ Listing: Psychedelics Game-Changer

The Psychedelics Revolution: From ‘War on Drugs’ To Funding Psychedelic Drug Research

Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD

Psychedelic Stocks
NEWS
INDUSTRY
INVESTING
COMPANIES
EXCLUSIVE

Newsletter

Get The Seed Investor straight to your email.

Copyright © 2016-2022, The Seed Investor | About | Contact | Advertise | Privacy Policy | Disclaimer
Powered by StructureCMS
The Seed Investor